Biogen’s Hemophilia Drug Delay May Push Sales to Mid-2014

Biogen Idec Inc., the maker of multiple sclerosis drugs Avonex, Tysabri and Tecfidera, said it anticipates bringing the hemophilia treatment Eloctate to market in mid-2014, later than previously projected.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.